Aloe Vera As a Potential Treatment For Gastrointestinal Inflammatory Diseases

Aloeride As a Potential Treatment For Gastrointestinal Inflammatory Diseases

Aloeride Aloe Vera has been found to effectively prevent and treat certain autoimmune diseases such as rheumatoid arthritis and ulcerative colitis. It has been shown aloe kills bacterium, which causes chronic duodenal and gastric ulcers caused by a bacterial infection. It has also been shown to reduce acid secretion. Drugs were discovered to reduce acid secretion, but people with ulcers did not seem to heal or their improvement would only be temporary. Then they would relapse and have more serious episodes of ulceration with all the painful symptoms. Chronic gastritis and stomach ulcers can lead to a tendency to cancer of the stomach, just as ulcerative colitis can lead to colon cancer. When looking into the studies of aloe you will find it decreases stomach acid production, which will protect the lining of the stomach from ulcers and it kills the bacteria, which has a tendency to lead to chronic stomach irritation. The following is a study on the effects of aloe vera on patients with inflammatory bowel disease while under therapeutic evaluation for their condition. The Aim is to assess the effects of aloe vera in vitro on the production of reactive oxygen metabolites, eiosanoids, and interleukin-8, which could be pathogens in inflammatory bowel disease. The Results were aloe vera gel had an inhibitory effect on reactive oxygen metabolite production; 50% inhibition at 1 in 1000 dilution and at 1 in 10-50 dilution with biopsies. Aloe vera inhibited the production of prostaglandin E2 by 30% at 1 in 50 dilution, but had no effect on thromboxane B2 production. The release of the interleukin-8 cells dropped by 20% with the aloe vera diluted at 1 in 100, but not a 1 in 10 or 1 in 1000 dilutions. The Conclusion of it all is the anti-inflammatory actions of aloe vera gel in vitro provide back up for the proposal aloe vera may have a therapeutic effect in inflammatory bowel disease. Another study performed on aloe vera to study it effectiveness with inflammatory bowel disease. The Aim of this study is to perform a double blind, randomized, placebo-controlled trial of the efficiency and safety of aloe vera gel for the treatment of mildly to moderate active ulcerative colitis. The Method will be to use forty-four hospital outpatients who could be evaluated were randomly given oral aloe gel or a placebo at 100 ml twice a day for 4 weeks, in a 2: 1 ratio. The primary outcome was clinical remission, sigmoidoscopic remission, and histological remission. The secondary outcome measures included changes in the Simple Clinical Colitis Activity Index, Baron score, histology score, hemoglobin, platelet count, erythrocyte sedimentation rate, C-reactive protein and albumin. The Results were clinical remission, improvement and responses in nine, about 30%, 11, about 37%, and 14, about 47% of the 30 patients who received the aloe vera gel compared with one, 7% and two, 14% of 14 patients taking placebo. The Simple Clinical Colitis Activity Index and histological scores decreased noticeably during treatment with aloe vera, compared to no decreases with the placebo. The Conclusion is aloe vera taken orally for 4 weeks produced a clinical response more often than placebo; it also reduced the histological disease activity and appeared to be safe. Additional evaluation of the potential of aloe vera gel is needed in inflammatory bowel disease.